Abstract: Objective：To analyze the risk factors of fever after transcatheter arterial chemoembolization (TACE) in patients with primary hepatocellular carcinoma (HCC) receiving oxaliplatin as the main regimen, and to predict the clinical outcomes. Methods：From January 2016 to January 2018, clinical data of patients with primary HCC who underwent TACE with oxaliplatin were retrospectively collected. All patients’ medical history, clinical data, biochemical examination, adverse reactions, and drug use were collected. Patients were divided into fever group and non-fever group. Risk factors were analyzed by multivariate logistic regression. Results：A total of 213 patients were collected, 41 in the fever group and 172 in the non-fever group, with a mean age of (58.1±11.6) years. The odds ratio (OR) value of preoperative alanine aminotransferase (ALT) was 1.013 (95% CI 1.000-1.026, P=0.047), preoperative fibrinogen (FIB) OR value was 1.005 (95% CI 1.001-1.008, P=0.007), preoperative Na+ OR value was 1.125 (95% CI 1.012-1.252, P=0.029), preoperative abnormal alpha fetoprotein (AFP; > 20 ng/mL) OR value was 3.118 (95% CI 1.293-7.521, P=0.011), the OR value of oxaliplatin dosage in TACE was 1.018 (95%CI 1.004-1.033, P=0.014). ROC analysis showed that the area under curve (AUC) of ALT, FIB, Na+, oxaliplatin dosage and iodized oil dosage ranged from 0.5 to 0.7, and the cut-off points were 28.5 U/L, 2 790 mg/L, 144.5 mmol/L, 125 mg, and 6.5 mL, respectively. Conclusions：The levels of ALT, FIB, Na+, AFP before TACE and oxaliplatin dosage during TACE are independent risk factors for post-embolization fever.